InterventionsAnimals

Semaglutide Demonstrates Cardiorenal Benefits in the SDT Fatty Rat, a New Model of Cardiovascular–Kidney–Metabolic Syndrome

ADA Scientific Sessions 2026 Abstract

The paper

BRIAND F, BOURDIER G, GRASSET E et al.

ADA Scientific Sessions 2026 Abstract · 5 Jun 2026

Presented at ADA Scientific Sessions 2026 · Poster 1370-P

doi.org/10.2337/db26-1370-p

Semaglutide may protect kidneys by reducing vascular resistance
Nature Medicine · 4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026